InvestorsHub Logo
icon url

north40000

12/20/17 11:29 AM

#12769 RE: CL101 #12768

Do you discount/disregard JNJ Dupuy/Synthes[Indiana, Pa.] and/or DuPuy Spine[Mass.] as a suitor, or as a competitor?
icon url

steve1der

12/20/17 11:34 AM

#12770 RE: CL101 #12768

Brilliant! We are all waiting for the big payday. Even though, I'm down 75% of my investment here, I'm sure we will all be zillionares soon!
icon url

dp60

12/20/17 11:54 AM

#12772 RE: CL101 #12768

CL101 , Thanks once again. Holiday greetings to you.

glta
icon url

boston745

12/20/17 1:07 PM

#12775 RE: CL101 #12768

Zimmer's new CEO which was Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group from Medtronic (Ranked #1 dominant in Spine Implants Market).



Glad you brought this up CL as this caught my attention too. The fact that the new CEO has strong spine experience is another clear signal that Zimmer intends to increase its revenues via the lucrative Spine market. Reading through old forums indicates that spine leadership is something Zimmer has lacked big time for well over a decade. Zimmer clearly intends on investing big in Spine.

New CEO strong spine & new Spine HQ in Colorado. Now they just need the right president to takeover their spine division and to acquire Amedica's Si3N4 tech!
icon url

dp60

12/20/17 6:13 PM

#12781 RE: CL101 #12768

CL101, I'm also very curious how AMDA would be valued (compared with LDR) in a merger scenario especially regarding the below intangible assets categories.




Data from Zimmer Annual report figures regarding LDR merger:

Intangible assets not subject to amortization:

In-process research and development (IPR&D) 2.0 mil

Intangible assets subject to amortization:

Technology 452.0 mil

Customer relationships 118.0

Trademarks and trade names 71.0

Other assets 76.8

Goodwill 482.4